Cargando…

Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis

OBJECTIVE: To improve the characterization of asymptomatic subjects with brain magnetic resonance imaging (MRI) abnormalities highly suggestive of multiple sclerosis (MS), a condition named as “radiologically isolated syndrome” (RIS). METHODS: Quantitative MRI metrics such as brain volumes and magne...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Stefano, Nicola, Stromillo, Maria Laura, Rossi, Francesca, Battaglini, Marco, Giorgio, Antonio, Portaccio, Emilio, Hakiki, Bahia, Malentacchi, Gianmichele, Gasperini, Claudio, Santangelo, Mario, Bartolozzi, Maria Letizia, Sormani, Maria Pia, Federico, Antonio, Amato, Maria Pia
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084867/ https://www.ncbi.nlm.nih.gov/pubmed/21559385 http://dx.doi.org/10.1371/journal.pone.0019452

Ejemplares similares

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis
por: Rossi, Francesca, et al.
Publicado: (2012)

Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability
por: Giorgio, Antonio, et al.
Publicado: (2017)

Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization
por: De Stefano, Nicola, et al.
Publicado: (2021)

Cognitive Issues in Pediatric Multiple Sclerosis
por: Portaccio, Emilio, et al.
Publicado: (2021)

Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis
por: Giorgio, Antonio, et al.
Publicado: (2020)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey
por: Portaccio, Emilio, et al.
Publicado: (2021)

An Italian programme for COVID-19 infection in multiple sclerosis
por: Sormani, Maria Pia
Publicado: (2020)

Modeling the Distribution of New MRI Cortical Lesions in Multiple Sclerosis Longitudinal Studies
por: Sormani, Maria Pia, et al.
Publicado: (2011)

Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
por: Pastò, Luisa, et al.
Publicado: (2012)

Cognitive clinico‐radiological paradox in early stages of multiple sclerosis
por: Uher, Tomas, et al.
Publicado: (2017)

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
por: Pecori, Chiara, et al.
Publicado: (2014)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
por: Giannini, Marta, et al.
Publicado: (2012)

Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis
por: Amato, Maria Pia, et al.
Publicado: (2022)

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population
por: Goretti, Benedetta, et al.
Publicado: (2014)

Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis
por: Fonderico, Mattia, et al.
Publicado: (2021)

How often do patients ask for the results of their radiological studies?
por: Capaccio, Enrico, et al.
Publicado: (2010)

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
por: Iaffaldano, Pietro, et al.
Publicado: (2012)

A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients
por: Niccolai, Claudia, et al.
Publicado: (2015)

Increased CD8(+) T cell responses to apoptotic T cell-associated antigens in multiple sclerosis
por: Lolli, Francesco, et al.
Publicado: (2013)

Assessing heterogeneity of treatment effect in multiple sclerosis trials
por: Sormani, Maria Pia, et al.
Publicado: (2023)

COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis
por: Albanese, Angela, et al.
Publicado: (2022)

Quantitative Assessment of Finger Motor Impairment in Multiple Sclerosis
por: Bonzano, Laura, et al.
Publicado: (2013)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
por: Branger, Pierre, et al.
Publicado: (2016)

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies
por: Bellinvia, Angelo, et al.
Publicado: (2022)

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
por: Portaccio, Emilio
Publicado: (2011)

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

A Comprehensive Review on Copemyl(®)
por: Annovazzi, Pietro, et al.
Publicado: (2017)

Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl(®)
por: Annovazzi, Pietro, et al.
Publicado: (2018)

Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis
por: Portaccio, Emilio, et al.
Publicado: (2021)

Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis
por: Schiavetti, Irene, et al.
Publicado: (2022)

Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register
por: Mosconi, Paola, et al.
Publicado: (2023)

Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event
por: Okuda, Darin T., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ij1pumt9sle9l37hgusd5dip2t